Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.
Recent
Upcoming
Share :

EHA Congress 2023

8 - 11 Jun 2023
Messe Frankfurt, Frankfurt, Germany
Videos
News
Real-world use of brexu-cel shows benefit in R/R mantle cell lymphoma treatment
Dr Nausheen Ahmed - The University of Kansas Cancer, Kansas, USA
Real-world use of brexu-cel shows benefit in R/R mantle cell lymphoma treatment ( Dr Nausheen Ahmed - The University of Kansas Cancer, Kansas, USA )
23 Jun 2023
Venetoclax and ibrutinib therapy shows favourable results in the treatment of R...
Prof Arnon Kater - Amsterdam UMC, Amsterdam, Netherlands
Venetoclax and ibrutinib therapy shows favourable results in the treatment of R/R chronic lymphocytic leukaemia ( Prof Arnon Kater - Amsterdam UMC, Amsterdam, Netherlands )
22 Jun 2023
Selinexor, bortezomib and dexamethasone shows PFS benefit for multiple myeloma
Dr Maria-Victoria Mateos - University Hospital Salamanca, Salamanca, Spain
Selinexor, bortezomib and dexamethasone shows PFS benefit for multiple myeloma ( Dr Maria-Victoria Mateos - University Hospital Salamanca, Salamanca, Spain )
19 Jun 2023
ADCLEC.syn1 and CD33-CARS in humanised acute myeloid leukaemia models shows...
Dr Sascha Haubner - Memorial Sloan Kettering Cancer Center, New York City, USA
ADCLEC.syn1 and CD33-CARS in humanised acute myeloid leukaemia models shows promising efficacy ( Dr Sascha Haubner - Memorial Sloan Kettering Cancer Center, New York City, USA )
19 Jun 2023
Ide-cel significantly prolongs PFS for r/r multiple myeloma versus standard...
Dr Krina Patel - MD Anderson Cancer Center, Houston, USA
Ide-cel significantly prolongs PFS for r/r multiple myeloma versus standard regimens ( Dr Krina Patel - MD Anderson Cancer Center, Houston, USA )
19 Jun 2023
A randomised trial of the FLT3 inhibitor gilteritinib as post-transplant...
Dr Mark Levis - Johns Hopkins Sidney Kimmel Comprehensive Cancer Center...
A randomised trial of the FLT3 inhibitor gilteritinib as post-transplant maintenance for FLT3-ITD AML ( Dr Mark Levis - Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, USA )
16 Jun 2023
Single infusion of cilta-cel sees longer median PFS than any previously...
Dr Nikhil Munshi - Dana-Farber Cancer Institute, Boston, USA
Single infusion of cilta-cel sees longer median PFS than any previously reported therapy in heavily pretreated RRMM ( Dr Nikhil Munshi - Dana-Farber Cancer Institute, Boston, USA )
16 Jun 2023
Atezolizumab, obinutuzumab and venetoclax combination is active and leads to...
Prof Anna Maria Frustaci - Niguarda Ca’ Granda Hospital, Milan, Italy
Atezolizumab, obinutuzumab and venetoclax combination is active and leads to durable remissions in previously untreated DLBCL-RS ( Prof Anna Maria Frustaci - Niguarda Ca’ Granda Hospital, Milan, Italy )
16 Jun 2023
Addition of blinatumomab to mini-hyper-CVD and inotuzumab improves outcomes in...
Dr Nicholas Short - MD Anderson Cancer Center, Houston, USA
Addition of blinatumomab to mini-hyper-CVD and inotuzumab improves outcomes in R/R ALL ( Dr Nicholas Short - MD Anderson Cancer Center, Houston, USA )
16 Jun 2023
Chemotherapy-free combination of ponatinib and blinatumomab results in high...
Dr Nicholas Short - MD Anderson Cancer Center, Houston, USA
Chemotherapy-free combination of ponatinib and blinatumomab results in high rates of CMR and NGS MRD negativity in Ph positive ALL ( Dr Nicholas Short - MD Anderson Cancer Center, Houston, USA )
16 Jun 2023
Ponatinib superior to imatinib in combination with reduced-intensity...
Dr Elias Jabbour - MD Anderson Cancer Center, Houston, USA
Ponatinib superior to imatinib in combination with reduced-intensity chemotherapy in newly diagnosed Ph positive ALL ( Dr Elias Jabbour - MD Anderson Cancer Center, Houston, USA )
15 Jun 2023
Efficacy and safety of belantamab mafodotin vs pomalidomide plus dexamethasone...
Prof Meletios Dimopoulos - National and Kapodistrian University of Athens...
Efficacy and safety of belantamab mafodotin vs pomalidomide plus dexamethasone in relapsed/refractory multiple myeloma ( Prof Meletios Dimopoulos - National and Kapodistrian University of Athens, Athens, Greece )
15 Jun 2023
Belamaf monotherapy induced rapid responses without unexpected toxicity in...
Dr Efstathios Kastritis - National and Kapodistrian University of Athens...
Belamaf monotherapy induced rapid responses without unexpected toxicity in relapsed or refractory light chain amyloidosis ( Dr Efstathios Kastritis - National and Kapodistrian University of Athens, Athens, Greece )
15 Jun 2023
Triplets for newly diagnosed unfit AML patients could be feasible with...
Dr Juan Miguel Bergua Burgues - Hospital San Pedro de Alcántara, Cáceres, Spain
Triplets for newly diagnosed unfit AML patients could be feasible with substantial venetoclax reduction ( Dr Juan Miguel Bergua Burgues - Hospital San Pedro de Alcántara, Cáceres, Spain )
15 Jun 2023

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation

An Error Occurred: Internal Server Error

Oops! An Error Occurred

The server returned a "500 Internal Server Error".

Something is broken. Please let us know what you were doing when this error occurred. We will fix it as soon as possible. Sorry for any inconvenience caused.